
Pfizer and Eli Lilly will resume Phase III clinical trials of tanezumab following the FDA lifting a ban on trials …
Pfizer has been told by the FDA to suspend trials of its novel injectable biotherapeutic tanezumab for chronic low back …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

